12,427 Shares in Revvity, Inc. (NYSE:RVTY) Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd acquired a new stake in Revvity, Inc. (NYSE:RVTY - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,427 shares of the company's stock, valued at approximately $1,358,000.

Several other large investors also recently modified their holdings of RVTY. Vanguard Group Inc. bought a new stake in shares of Revvity in the third quarter valued at about $1,579,487,000. Ceredex Value Advisors LLC bought a new stake in Revvity during the fourth quarter worth about $108,353,000. Sumitomo Mitsui Trust Holdings Inc. bought a new position in Revvity in the 4th quarter valued at about $33,568,000. Boston Trust Walden Corp acquired a new position in shares of Revvity in the 4th quarter valued at approximately $25,154,000. Finally, KBC Group NV acquired a new stake in shares of Revvity during the 3rd quarter worth approximately $25,301,000. 86.65% of the stock is owned by institutional investors.

Insider Buying and Selling at Revvity

In other news, insider Prahlad R. Singh sold 21,217 shares of the company's stock in a transaction on Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares in the company, valued at approximately $9,677,288.28. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.60% of the company's stock.

Revvity Stock Down 0.6 %

Shares of RVTY stock traded down $0.59 on Thursday, reaching $102.09. 461,111 shares of the company were exchanged, compared to its average volume of 849,016. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77. The company has a 50-day moving average of $104.72 and a 200-day moving average of $101.50. The company has a market cap of $12.61 billion, a price-to-earnings ratio of 18.56, a PEG ratio of 2.69 and a beta of 1.09. Revvity, Inc. has a one year low of $79.50 and a one year high of $132.54.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating analysts' consensus estimates of $1.15 by $0.10. The firm had revenue of $695.90 million during the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. Analysts anticipate that Revvity, Inc. will post 4.65 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be issued a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.27%. Revvity's payout ratio is 5.09%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on RVTY. UBS Group cut Revvity from a "buy" rating to a "neutral" rating and lifted their target price for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Stifel Nicolaus upped their price target on shares of Revvity from $95.00 to $110.00 and gave the stock a "hold" rating in a report on Friday, February 2nd. KeyCorp increased their price target on Revvity from $110.00 to $126.00 and gave the company an "overweight" rating in a research note on Friday, February 2nd. Raymond James boosted their price objective on Revvity from $106.00 to $127.00 and gave the stock an "outperform" rating in a research report on Friday, February 2nd. Finally, Barclays boosted their price target on Revvity from $92.00 to $105.00 and gave the stock an "equal weight" rating in a report on Thursday, January 25th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, Revvity has an average rating of "Moderate Buy" and an average price target of $118.91.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.